Animals with colitis administered with RL-FNPs expressively reduced the expression of TNF-α, IL-1β, IL-6, and IL-12, with effectiveness comparable to that of the dexamethasone group, with the exception of IL-12. The gene discussed is IL6; the disease is colitis.